Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke - A statement for health care professionals from the CRP pooling project members

被引:238
作者
Di Napoli, M
Schwaninger, M
Cappelli, R
Ceccarelli, E
Di Gianfilippo, G
Donati, C
Emsley, HCA
Forconi, S
Hopkins, SJ
Masotti, L
Muir, KW
Paciucci, A
Papa, F
Roncacci, S
Sander, D
Sander, K
Smith, CJ
Stefanini, A
Weber, D
机构
[1] SMDN Ctr Cardiovasc Med & Cerebrovasc Dis Prevent, Neurol Sect, I-67039 Laquila, Italy
[2] San Camillo de Lellis Gen Hosp, Neurol Serv, Rieti, Italy
[3] Heidelberg Univ, Neurol Klin, Heidelberg, Germany
[4] Univ Siena, Dept Internal Cardiovasc & Geriatr Med, I-53100 Siena, Italy
[5] Univ Liverpool, Walton Ctr Neurol & Neurosurg, Div Neurosci, Liverpool L69 3BX, Merseyside, England
[6] Univ Manchester, Hope Hosp, Div Med & Neurosci Hope, Salford M6 8HD, Lancs, England
[7] Cecina Hosp, Cecina, Livorno, Italy
[8] Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Div Clin Neurosci, Glasgow, Lanark, Scotland
[9] Tech Univ Munich, Dept Neurol, D-8000 Munich, Germany
关键词
aspirin; cerebrovascular disorders; inflammation; meta-analysis; mortality; prevention; risk factors; scientific statements;
D O I
10.1161/01.STR.0000165929.78756.ed
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose - Several studies have shown, in different populations, that modest elevation of plasma C-reactive protein (CRP) in the range seen in apparently healthy individuals is a strong predictor of future vascular events. Elevated plasma CRP concentrations are also associated with an increased risk of cerebrovascular events and an increased risk of fatal and nonfatal cardiovascular events in ischemic stroke patients. These epidemiological and clinical observations suggest that determination of plasma CRP concentrations could be used as an adjunct for risk assessment in primary and secondary prevention of cerebrovascular disease and be of prognostic value. The aim of this review is to summarize the evidence for CRP as an independent predictor of cerebrovascular events in at-risk individuals and ischemic stroke patients and to consider its usefulness in evaluating prognosis after stroke. Summary of Review - CRP fulfils most of the requirements of a new risk and prognostic predictor, but several issues await further confirmation and clarification before this marker can be included in the routine evaluation of stroke patients and subjects at risk for cerebrovascular disease. Potentially important associations have been established between elevated plasma CRP concentrations and increased efficacy of established therapies, particularly lipid-lowering therapy with statins. Conclusion - At present, there is not sufficient evidence to recommend measurement of CRP in the routine evaluation of cerebrovascular disease risk in primary prevention, because there is insufficient evidence as to whether early detection, or intervention based on detection, improves health outcomes, although shared risk of cardiovascular disease indicates this may be of value. In secondary prevention of stroke, elevated CRP adds to existing prognostic markers, but it remains to be established whether specific therapeutic options can be derived from this.
引用
收藏
页码:1316 / 1329
页数:14
相关论文
共 193 条
[11]   Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women [J].
Bermudez, EA ;
Rifai, N ;
Buring, J ;
Manson, JE ;
Ridker, PA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (10) :1668-1673
[12]   C-Reactive protein in acute myocardial infarction: Association with heart failure [J].
Berton, G ;
Cordiano, R ;
Palmieri, R ;
Pianca, S ;
Pagliara, V ;
Palatini, P .
AMERICAN HEART JOURNAL, 2003, 145 (06) :1094-+
[13]   The major receptor for C-reactive protein on leukocytes is Fcγ receptor II [J].
Bharadwaj, D ;
Stein, MP ;
Volzer, M ;
Mold, C ;
Du Clos, TW .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (04) :585-590
[14]   A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women [J].
Blake, GJ ;
Dada, N ;
Fox, JC ;
Manson, JE ;
Ridker, PM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (05) :1302-1306
[15]   Blood pressure, C-reactive protein, and risk of future cardiovascular events [J].
Blake, GJ ;
Rifai, N ;
Buring, JE ;
Ridker, PM .
CIRCULATION, 2003, 108 (24) :2993-2999
[16]   Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia [J].
Blake, GJ ;
Ridker, PM ;
Kuntz, KM .
AMERICAN JOURNAL OF MEDICINE, 2003, 114 (06) :485-494
[17]   Coronary heart disease risk reduction in a predominantly beer-drinking population [J].
Brenner, H ;
Rothenbacher, D ;
Bode, G ;
März, W ;
Hoffmeister, A ;
Koenig, W .
EPIDEMIOLOGY, 2001, 12 (04) :390-395
[18]   Human CRP gene polymorphism influences CRP levels - Implications for the prediction and pathogenesis of coronary heart disease [J].
Brull, DJ ;
Serrano, N ;
Zito, F ;
Jones, L ;
Montgomery, HE ;
Rumley, A ;
Sharma, P ;
Lowe, GDO ;
World, MJ ;
Humphries, SE ;
Hingorani, AD .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (11) :2063-2069
[19]   The role of interleukin-6 in stress-induced hyperthermia and emotional behaviour in mice [J].
Butterweck, V ;
Prinz, S ;
Schwaninger, M .
BEHAVIOURAL BRAIN RESEARCH, 2003, 144 (1-2) :49-56
[20]   C-reactive protein (CRP) in cerebro-vascular events [J].
Canova, CR ;
Courtin, C ;
Reinhart, WH .
ATHEROSCLEROSIS, 1999, 147 (01) :49-53